Dr. Sina Bavari received his Ph.D. in Immunotoxicology and Pharmaceutical Science at the University of Nebraska Medical Center in Omaha, Nebraska. He is currently serving as Chief Scientific Officer, Scientific Director at US Army Research Institute of Infectious Diseases (USAMRIID) and has held numerous leadership roles at USAMRIID, including Chief, Molecular and Translational Sciences Division and Therapeutic Discovery Center; Chief, Target Discovery & Experimental Microbiology, Integrated Toxicology Division; and Chief, Immunology, Target Identification, and Translational Research, Bacteriology Division. He has produced approximately 30 patents, and out-licensed many products.
Dr. Bavari has published nearly 200 manuscripts in high impact journals, contributed to 15 development candidates, as well as numerous IND filings. He has managed complex programs by galvanizing strong collaborations with key internal and external partners which includes other government agencies; academic Institutions and small to large pharmaceutical organizations. Dr. Bavari's group has developed, standardized, and successfully finished multiple large screens, using authentic highly pathogenic viruses including filoviruses. He has an extensive understanding of therapeutic countermeasures against filoviruses including; polymerase inhibitors and nucleic acid based targeted approaches. Dr. Bavari is very familiar with animal models for filoviruses. He has been deeply involved with many clinical studies and currently oversees or participates in 28 discoveries, 11 preclinical, and 3 clinical stage candidate antivirals against Ebola virus.
